The substituted methylenedioxyphenethylamines (abbreviated as MDxx) represent a diverse chemical class of compounds derived from phenethylamines. This category encompasses numerous psychoactive substances with entactogenic, psychedelic, and/or stimulant properties, in addition to entheogens. These compounds find application as research chemicals, designer drugs, and recreational substances. [1]
The base compound of the MDxx class is 3,4-methylenedioxyphenethylamine (MDPEA), and the prototypical agent of this class is 3,4-methylenedioxy-N-methylamphetamine (MDMA; "ecstasy"). Other mentionables include 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxy-N-ethylamphetamine (MDEA; "Eve"), N-methyl-1,3-benzodioxolylbutanamine (MBDB; "Eden"), and 3,4-methylenedioxy-N-methylcathinone (βk-MDMA; "Methylone").
The compounds most commonly regarded as comprising the family of MDxx derivatives include:
In addition, there are a number of other compounds that have some structural and pharmacological similarities to the methylenedioxyphenethylamines, and are useful for comparison. These can be broadly divided into (i) compounds where the methylenedioxyphenyl ring is retained but the phenethyl portion is modified, or (ii) compounds which retain the 3,4-cyclised amphetamine core common to the MDxx compounds, but have the 1,3-benzodioxole ring replaced by related heterocycles.
Structure | Chemical Name | Abbreviations | Other Names | CAS number | Ref |
---|---|---|---|---|---|
3,4-Methylenedioxyphenyl-1-propene | Isosafrole | 120-58-1 | |||
3,4-Methylenedioxyphenyl-2-propene | Safrole, Shikimol | 94-59-7 | |||
4,5-Methylenedioxyphenyl-3-methoxy-2-propene | Myristicin | 607-91-0 | |||
3,4-Methylenedioxyphenyl-1-propanone | MDP1P | 28281-49-4 | |||
3,4-Methylenedioxyphenyl-2-propanone | MDP2P | 4676-39-5 | |||
3,4-Methylenedioxybenzaldehyde | Piperonal | 120-57-0 | |||
3,4-Methylenedioxyphenol | Sesamol | 533-31-3 | |||
5-(3,4-Methylenedioxyphenyl)-2,4-pentadienoyl-2-piperidine | Piperine (also chavicine) | 94-62-2 | |||
3,4-Methylenedioxycinnamylpiperidine | Ilepcimide | 23434-86-8 | |||
trans-4-(4-Fluorophenyl)-3-[(3,4-methylenedioxy)phenoxy]methylpiperidine | Paroxetine | 61869-08-7 | |||
5,6-Methylenedioxy-2-aminoindane | 5,6-MDAI, MDAI | 132741-81-2 | |||
5,6-Methylenedioxy-N-methyl-2-aminoindane | 5,6-MDMAI, MDMAI | 132741-82-3 | |||
6,7-Methylenedioxy-2-aminotetralin | 6,7-MDAT | 101625-35-8 | |||
6,7-Methylenedioxy-2-methylaminotetralin | 6,7-MDMAT | 34620-52-5 | |||
3,4-Methylenedioxy-1-benzylpiperazine | MDBZP | Piperonylpiperazine | 32231-06-4 | ||
3,4-Methylenedioxy-α-pyrrolidinopropiophenone | MDPPP | 783241-66-7 | |||
3',4'-Methylenedioxy-α-pyrrolidinobutiophenone | MDPBP | 784985-33-7 | |||
3,4-Methylenedioxy-α-pyrrolidinopentiophenone | MDPV | 687603-66-3 | |||
3,4-Methylenedioxy-α-pyrrolidinohexiophenone | MDPHP | 776994-64-0 | |||
Methylenedioxyphenmetrazine | MDPM | 3,4-Methylenedioxyphenmetrazine | [3] | ||
Methyl (1,3-benzodioxol-5-yl)(piperidin-2-yl)acetate | MDMPH | 3,4-Methylenedioxymethylphenidate | |||
4-Methyl-5-(1,3-benzodioxol-5-yl)-4,5-dihydro-1,3-oxazol-2-amine | MDMAR | 3',4'-Methylenedioxy-4-methylaminorex | 1445573-16-9 | ||
1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-2,3-benzodiazepine | GYKI-52895 | 869360-93-0 | |||
3,4-Ethylidenedioxyamphetamine | EIDA | 125299-84-5 | |||
3,4-isopropylidenedioxyamphetamine | IDA | ||||
1-(2,2-Difluoro-1,3-benzodioxol-5-yl)propan-2-amine | DFMDA | 910393-51-0 | |||
6-(2-aminopropyl)-5-methoxy-1,3-benzoxathiol | 4T-MMDA-2 | 133787-69-6 | |||
1-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-methylpropan-2-amine | EDMA | 133787-66-3 | |||
1-(2,3-Dihydro-1-benzofuran-5-yl)propan-2-amine | 5-APDB | 152624-03-8 | |||
1-(1,3-dihydro-2-benzofuran-5-yl)-N-methylpropan-2-amine | IBF5MAP | 201407-56-9 | |||
1-(2,3-Dihydro-1-benzofuran-6-yl)propan-2-amine | 6-APDB | 152623-93-3 | |||
1-(1-benzofuran-5-yl)propan-2-amine | 5-APB | 286834-81-9 | |||
N-methyl-1-(1-benzofuran-5-yl)propan-2-amine | 5-MAPB | 1354631-77-8 | |||
N-ethyl-1-(1-benzofuran-5-yl)propan-2-amine | 5-EAPB | 1445566-01-7 | |||
N-methyl-1-(1-benzofuran-5-yl)butan-2-amine | 5-MBPB | ||||
1-(1-benzofuran-6-yl)propan-2-amine | 6-APB | 286834-85-3 | |||
N-methyl-1-(1-benzofuran-6-yl)propan-2-amine | 6-MAPB | 1354631-79-0 | |||
1-(2,3-dihydro-1H-inden-5-yl)propan-2-amine | 5-APDI | IAP | 13396-94-6 | ||
1-(2,3-dihydro-1H-inden-5-yl)-N-methylpropan-2-amine | 5-MAPDI | IMP | 1310153-27-5 | ||
1-(5,6,7,8-tetrahydronaphthalen-2-yl)propan-2-amine | 6-APT | TAP | 3160-20-1 | ||
1-(naphthalen-2-yl)propan-2-amine | NAP | PAL-287 | 18085-03-5 | ||
N-methyl-1-(naphthalen-2-yl)propan-2-amine | MNAP | Methamnetamine (PAL-1046) | 1178720-66-5 | ||
1-(1-benzothiophen-5-yl)propan-2-amine | 5-APBT | 1368128-53-3 | |||
1-(1H-indol-5-yl)propan-2-amine | 5-API | 5-IT | 3784-30-3 | ||
1-(1H-1,3-benzodiazol-5-yl)propan-2-amine | 752145-76-9 | ||||
1-(1,3-benzoxazol-5-yl)propan-2-amine | 1368557-51-0 | ||||
1-(1,3-benzothiazol-6-yl)propan-2-amine | 1896565-11-9 | ||||
1-(2,1,3-benzoxadiazol-5-yl)propan-2-amine | 910413-33-1 | ||||
1-{imidazo[1,2-a]pyridin-6-yl}propan-2-amine | 1337128-11-6 | ||||
1-(1,2,3-benzothiadiazol-5-yl)propan-2-amine | 1380044-39-2 | ||||
1-(quinoxalin-6-yl)propan-2-amine | 910407-54-4 | ||||
1-(1,3-Benzodiazol-5-yl)-N-methylpropan-2-amine | |||||
1-(2,1,3-Benzoxadiazol-5-yl)-N-methylpropan-2-amine | ODMA | 2567501-96-4 | |||
1-(2,1,3-Benzothiadiazol-5-yl)-N-methylpropan-2-amine | TDMA | 2302389-87-1 | |||
1-(2,1,3-Benzoselenadiazol-5-yl)-N-methylpropan-2-amine | SeDMA | ||||
1-(Benzo[d][1,3]oxathiol-5-yl)-N-methylpropan-2-amine | MY100 | [4] [5] | |||
1-(Benzo[d][1,3]oxathiol-5-yl)-N,N-dimethylpropan-2-amine | MY101 | [4] [6] | |||
1-(Benzo[d][1,3]oxathiol-6-yl)-N-methylpropan-2-amine | MY200 | [4] [7] | |||
1-(Benzo[b]thiophen-6-yl)-N-methylpropan-2-amine | MY300 | [4] [8] | |||
1-(Benzo[b]thiophen-5-yl)-N-methylpropan-2-amine | 5-MAPBT | MY400 | 2613382-32-2 | [4] [9] | |
1-(Benzo[d]thiazol-5-yl)-N-methylpropan-2-amine | 5-BZT-MDMA | MYCO-006? | [10] [11] [12] [13] | ||
1-(Benzo[d]thiazol-6-yl)-N-methylpropan-2-amine | 6-BZT-MDMA | MYCO-007? | [10] [14] [12] [13] | ||
? | MYCO-002 | [15] [16] [17] |
PiHKAL: A Chemical Love Story is a book by Alexander Shulgin and Ann Shulgin, published in 1991. The subject of the work is psychoactive phenethylamine chemical derivatives, notably those that act as psychedelics and/or empathogen-entactogens. The main title, PiHKAL, is an acronym that stands for "Phenethylamines I Have Known and Loved".
3,4-Methylenedioxyamphetamine (MDA), sometimes referred to as “sass,” is an empathogen-entactogen, stimulant, and psychedelic drug of the amphetamine family that is encountered mainly as a recreational drug. In its pharmacology, MDA is a serotonin–norepinephrine–dopamine releasing agent (SNDRA). In most countries, the drug is a controlled substance and its possession and sale are illegal.
MBDB, also known as N-methyl-1,3-benzodioxolylbutanamine or as 3,4-methylenedioxy-N-methyl-α-ethylphenylethylamine, is an entactogen of the phenethylamine, amphetamine, and phenylisobutylamine families related to MDMA. It is known by the street names "Eden" and "Methyl-J".
3,4-Methylenedioxyphenylpropan-2-one or piperonyl methyl ketone is a chemical compound consisting of a phenylacetone moiety substituted with a methylenedioxy functional group. It is commonly synthesized from either safrole or its isomer isosafrole via oxidation using the Wacker oxidation or peroxyacid oxidation methods. MDP2P is unstable at room temperature and must be kept in the freezer in order to be preserved properly.
2C (2C-x) is a general name for the family of psychedelic phenethylamines containing methoxy groups on the 2 and 5 positions of a benzene ring. Most of these compounds also carry lipophilic substituents at the 4 position, usually resulting in more potent and more metabolically stable and longer acting compounds. Most of the currently known 2C compounds were first synthesized by Alexander Shulgin in the 1970s and 1980s and published in his book PiHKAL. Shulgin also coined the term 2C, being an acronym for the 2 carbon atoms between the benzene ring and the amino group.
5-Methoxy-3,4-methylenedioxymethamphetamine is a designer drug of the substituted methylenedioxyphenethylamine (MDxx) class. Little is known about its effects and it has not been formally studied in animals.
Metaescaline (3,4-dimethoxy-5-ethoxyphenethylamine) is a lesser-known psychedelic drug. It is an analog of mescaline. Metaescaline was first synthesized by Alexander Shulgin. In his book PiHKAL, the dosage range is listed as 200–350 mg, and the duration listed as 8–12 hours. Metaescaline produces mental insights, entactogenic, MDMA-like effects, and TOMSO-like activation. Little data exists about the pharmacological properties, metabolism, and toxicity of metaescaline, though it has been studied to a limited extent in comparison with other related compounds.
3,4-Methylenedioxy-N-hydroxy-N-methylamphetamine is an entactogen, psychedelic, and stimulant of the phenethylamine and amphetamine chemical classes. It is the N-hydroxy homologue of MDMA ("Ecstasy"), and the N-methyl homologue of MDOH. MDHMA was first synthesized and assayed by Alexander Shulgin. In his book PiHKAL, Shulgin listed the dosage range as 100–160 mg, and the duration as approximately 4–8 hours. He describes MDHMA as causing entactogenic and open MDMA-like effects, easing communication, and increasing appreciation of the senses.
BOH, also known as 3,4-methylenedioxy-β-methoxyphenethylamine, is a drug of the phenethylamine class. It is the β-methoxy analog of methylenedioxyphenethylamine (MDPEA) and is also more distantly related to methylone. On account of its similarity to norepinephrine, the effects of BOH may be of a purely adrenergic nature.
2,5-Dimethoxy-3,4-methylenedioxyamphetamine is a lesser-known psychedelic drug of the phenethylamine and amphetamine chemical classes. It was first synthesized by Alexander Shulgin and was described in his book PiHKAL. Shulgin listed the dosage as 30–75 mg and the duration as 6–8 hours. He reported DMMDA as producing LSD-like images, mydriasis, ataxia, and time dilation. DMMDA isn't mentioned much in literature outside PiHKAL unlike 2C-B.
1,3-Benzodioxolylbutanamine is an entactogenic drug of the phenethylamine, amphetamine, and phenylisobutylamine families. It is the α-ethyl analog of MDPEA and MDA and the methylenedioxy analogue of α-ethylphenethylamine.
N-Ethyl-1,3-benzodioxolylpentanamine is a psychoactive drug and member of the phenethylamine chemical class which acts as an entactogen, psychedelic, and stimulant. It is the N-ethyl analog of 1,3-benzodioxolylpentanamine. Ethyl-K was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 40 mg and the duration is unknown. Very little is known about the pharmacology, pharmacokinetics, effects, and toxicity of Ethyl-K.
3,4-Methylenedioxy-N,N-dimethylamphetamine is a lesser-known research chemical. It is also the N,N-dimethyl analog of 3,4-methylenedioxyamphetamine (MDA). MDDM was first synthesized by Alexander Shulgin. In his book PiHKAL , the dosage is unspecified and the duration unknown. MDDM produces only mild effects that are not well characterized in PiHKAL. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDDM. This compound is however occasionally encountered as an impurity in 3,4-methylenedioxy-N-methylamphetamine (MDMA) which has been synthesized by methylation of MDA using methylating reagents such as methyl iodide. An excess of reagent or a reaction temperature that is too high results in some double methylation of the amine nitrogen, yielding MDDM as well as MDMA. The presence of MDDM as an impurity can thus reveal which synthetic route was used to manufacture seized samples of MDMA.
A monoamine releasing agent (MRA), or simply monoamine releaser, is a drug that induces the release of one or more monoamine neurotransmitters from the presynaptic neuron into the synapse, leading to an increase in the extracellular concentrations of the neurotransmitters and hence enhanced signaling by those neurotransmitters. The monoamine neurotransmitters include serotonin, norepinephrine, and dopamine; monoamine releasing agents can induce the release of one or more of these neurotransmitters.
Substituted phenethylamines are a chemical class of organic compounds that are based upon the phenethylamine structure; the class is composed of all the derivative compounds of phenethylamine which can be formed by replacing, or substituting, one or more hydrogen atoms in the phenethylamine core structure with substituents.
3,4-Methylenedioxy-N-ethylamphetamine is an empathogenic psychoactive drug. MDEA is a substituted amphetamine and a substituted methylenedioxyphenethylamine. MDEA acts as a serotonin, norepinephrine, and dopamine releasing agent and reuptake inhibitor.
4-Substituted-2,5-dimethoxyamphetamines (DOx) is a chemical class of substituted amphetamine derivatives featuring methoxy groups at the 2- and 5- positions of the phenyl ring, and a substituent such as alkyl or halogen at the 4- position of the phenyl ring. Most compounds of this class are potent and long-lasting psychedelic drugs, and act as highly selective 5-HT2A, 5-HT2B, and 5-HT2C receptor partial agonists. A few bulkier derivatives such as DOAM have similarly high binding affinity for 5-HT2 receptors but instead act as antagonists, and so do not produce psychedelic effects though they retain amphetamine-like stimulant effects.
MDMAT (6,7-methylenedioxy-N-methyl-2-aminotetralin) is a selective serotonin releasing agent (SSRA) and entactogen drug. It is the N-methylated derivative of MDAT, similarly to the relationship of MDMA to MDA. It has been theorized to have less long-term neurotoxicity and less hallucinogenic effects than other MDxx derivatives, but no formal scientific research has been conducted specifically on MDMAT.
Substituted tryptamines, or simply tryptamines, also known as serotonin analogues (i.e., 5-hydroxytryptamine analogues), are organic compounds which may be thought of as being derived from tryptamine itself. The molecular structures of all tryptamines contain an indole ring, joined to an amino (NH2) group via an ethyl (−CH2–CH2−) sidechain. In substituted tryptamines, the indole ring, sidechain, and/or amino group are modified by substituting another group for one of the hydrogen (H) atoms.
6-MAPDB is a chemical compound which might be an entactogenic drug. It is structurally related to drugs like 6-APDB and 6-MAPB, which have similar effects to MDMA and have been used as recreational drugs. 6-MAPDB has never been studied to determine its pharmacological activity, though it is the N-methyl derivative of 6-APDB which is known to be a selective serotonin releaser.
MYCO - 006 and 007 represent families of molecules that are based on MDMA molecules. MYCO -006 and MYCO – 007 have been developed in order to reduce the overall acute experience time of Generation 1 MDMA by increasing the metabolism properties of the drug.
Mydecine [...] announced it has successfully synthesized multiple short-acting MDMA analogs. This family of analogs have been specifically designed by experts at Mydecine to have a shorter half life than traditional MDMA. The Company has named this family of novel molecules MYCO-006 and have applied for patent coverage with the World Intellectual Property Organization.
MYCO - 002 is an entactogenic compound that has been created with the goal of reducing harm and improving the safety profile vs. traditional MDMA.